Loading
A phase 2/3 trial testing Trabedersen in pancreatic ductal adenocarcinoma, now recruiting.
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer is a phase 2/3 interventional study registered as NCT06079346, led by Oncotelic, and recruiting on the registry. Official title: A Randomised Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer. Planned enrolment is 455 participants (estimated). The study started in 2024-05-01 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.